Schedule By Day


 

* Saturday, April 25, 2020

 

6:00 AM – 2:00 PM

Speaker Ready Open (514)
 

6:30 AM – 2:00 PM

Registration Open (210 Foyer)
 

7:00 AM – 8:00 AM

Primary Audience: HF/HTX
Secondary Audience: LF/LTX, MCS, NHSAH, PEDS

Session Summary: This symposium will focus on sex, gender, and race-specific strategies in HTX: differences in advanced HF therapies (MCS vs inotropic support, complications of MCS, status listing); differences in HTX and implications of sex and race matching; cardiovascular risk factors in women (traditional and non-traditional); pregnancy in HTX recipients (preconception considerations, timing, cardiac assessment, maternal and fetal complications, breastfeeding, immunosuppression, contraception, ethics); gender awareness.

Chairs: Yael Peled, MD and Marta Farrero, MD
 
7:00 AM The Woman in Red: Sex Differences in Advanced Heart Failure Therapies and Outcomes
Eileen M. Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH, USA
7:15 AM Racial Differences in Advanced Heart Failure Therapies and Outcomes
Alanna A. Morris, MD, Emory University, Atlanta, GA, USA
7:30 AM Giving Birth After New Life: Pregnancy in Heart Transplant Recipients
Tuvia Ben Gal, MD, Rabin Medical Center, Petah Tikva, Israel
7:45 AM He/She/They: Gender Identity and Heart Transplant
Loreta Matheo, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
Primary Audience: LF/LTX
Secondary Audience: BSTR, PATH, PEDS

Session Summary: This session will give an update on the current status of blood and BAL biomarkers and early changes in pulmonary function, imaging, and pathology which might predict the development of CLAD and its specific phenotypes.

Chairs: Geert M. Verleden, MD, PhD, FERS and Federica Meloni, MD
 
7:00 AM Imaging, Pulmonary Function and Pathological Changes as Early Markers and Prognostic Sign for CLAD Phenotypes: How Predictable Are They?
Greg Snell, MD, The Alfred Hospital, Melbourne, Australia
7:20 AM Blood Biomarkers: Does Anything Stand at Present?
Sam S. Weigt, MD, UCLA Medical Center, Los Angeles, CA, USA
7:35 AM BAL Biomarkers: What's in the Name?
Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland
7:50 AM Panel Discussion
Primary Audience: HF/HTX
Secondary Audience: PEDS, PHARM

Session Summary: In this session, lecturers will speak about complications that decrease long-term survival post heart transplant cardiac allograft vasculopathy and malignancy, focusing on updated clinical evidence to prevent their onset and/or delay their progression. Complications related to proliferation signal inhibitors and their impact to prevent long-term complications and improve survival post-transplant will be discussed.

Chairs: David A. Baran, MD and Elena Sandoval, MEBCTS
 
7:00 AM What’s Beyond Ten Years? A Definition for Transplantopathy
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA
7:15 AM Facing the Facts: What Really Works and What Doesn’t to Prevent and Delay CAV?
Livia Goldraich, MD, Hospital de Clínicas Porto Alegre, Porto Alegre, Brazil
7:30 AM There Goes My Miracle: How Can We Prevent Post-Transplant Malignancies?
Sandrigo Mangini, MD, PhD, Heart Institute, Sao Paulo, Brazil
7:45 AM Panel Discussion
Primary Audience: PH
Secondary Audience: HF/HTX, LF/LTX, NHSAH, PEDS, PHARM

Session Summary: Advanced cardiopulmonary disease (both the disease and treatment) has a devastating effect of quality of life (QoL). Palliative care support as a treatment option is very much underutilized in patients with end stage heart and lung disease both before and after transplantation. This session will focus on how to integrate palliative care and improve QoL both before and after transplantation. A panel discussion with all speakers will conclude this session.

Chairs: Sasha Storaasli, MD and Sandeep Sahay, MD
 
7:00 AM CASE PRESENTATION: End-Stage Cardiopulmonary Disease
Sandeep Sahay, MD, Houston Methodist Hospital, Houston, TX, USA
7:05 AM A Breath of Fresh Air: Management of Dyspnea in End Stage Heart/Lung Disease
Rebecca Colman, MD, University of Toronto, Toronto, ON, Canada
7:20 AM This Could Go a Couple of Ways: Understanding How Preoperative Expectations of Quality of Life After Transplant Measure Up with Actual Experience
Meghan Aversa, MD, New York Presbyterian at Columbia University, New York, NY, USA
7:35 AM A Shared Reality: Seeing Through the Lens by All Providers, Starting Early
Eric Nolley, MD, MS, Johns Hopkins, Baltimore, MD, USA
7:50 AM Panel Discussion
Primary Audience: PHARM
Secondary Audience: MCS, NHSAH

Session Summary: This session will focus on anticoagulation strategies and monitoring in adult and pediatric patients on durable mechanical circulatory support (MCS). Anticoagulation bridging approaches, reversal methods, and anticoagulation monitoring strategies will be discussed.

Chairs: Douglas L. Jennings, PharmD and Georgina Waldman, PharmD
 
7:00 AM Phantom Menace: Anticoagulation Bridging for Durable MCS
Tara Veasey, PharmD, BCPS, Allegheny General Hospital, Pittsburgh, PA, USA
7:15 AM Q & A
7:20 AM A New Hope: Reversal of Bleeding for Durable MCS
Jean Connors, MD, Brigham and Women's Hospital, Boston, MA, USA
7:35 AM Q & A
7:40 AM Return of the Pharmacists: Pharmacist-Driven Anticoagulation for Durable MCS
Casandra Vale, BPharm, The Prince Charles Hospital, Queensland, Australia
7:55 AM Q & A
Primary Audience: PEDS
Secondary Audience: HF/HTX, PATH, PHARM

Session Summary: This session aims to discuss the greatest controversies that pediatric transplant providers have debated over the last decade. There will be three main topics.

Chairs: Shahnawaz Amdani, MD and Estela Azeka, MD
 
7:00 AM Why Be Positive When You Can Be Negative? The Utility of Virtual Crossmatch
Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY, USA
7:15 AM Q & A
7:20 AM To Be Old and Wise or Young and Stupid: Biopsy vs. Novel Non-Invasive Means to Diagnose Rejection
Annalisa Angelini, MD, University of Padua, Padua, Italy
7:35 AM Q & A
7:40 AM Referring the Fontan for Advanced Therapies: When, How, Why?
Leigh C. Reardon, MD, UCLA Medical Center, Los Angeles, CA, USA
7:55 AM Q & A
 

8:00 AM – 8:15 AM

Coffee Break
 

8:15 AM – 10:00 AM

Information on ISHLT2020 Oral Sessions will be available in January 2020
 

10:00 AM – 10:15 AM

Coffee Break
 

10:15 AM - 12:15 PM

Primary Audience: ALL

Chairs: Joseph G. Rogers, MD and Peter M. Hopkins, FRACP
 
10:15 AM Awards Presentation
10:28 AM Caves Award Winner Encore Presentation
10:35 AM Featured Abstract
10:50 AM Featured Abstract
11:05 AM Featured Abstract
11:20 AM CASE PRESENTATION: President's Debate
Melissa Cousino, PhD, C.S. Mott Children's Hospital, Ann Arbor, MI, USA
11:25 AM PRESIDENT'S DEBATE: Psychosocial Issues Alone are A Contraindication to Transplantation (PRO)
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands
11:45 AM PRESIDENT'S DEBATE: Psychosocial Issues Alone are a Contraindication to Transplantation (CON)
Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA
12:05 PM Debate Rebuttal (PRO)
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands
12:10 PM Debate Rebuttal (CON)
Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA
 

12:00 PM – 12:15 PM

Coffee Break
 

12:15 PM – 2:00 PM

Information on ISHLT2020 Oral Sessions will be available in January 2020

2:00 PM

Meeting Adjourns


*This schedule at a glance is updated each Friday to reflect any changes in information, including room names, session times, speaker information